Yujie Xie

Yujie Xie

Auto-generated profile, based on publicly available information

Yujie Xie

Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2025 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
SHSiqi Hu
Siqi Hu
QZQiong Zou
Qiong Zou
ZSZijie Shen
Zijie Shen
YXYujie Xie
Yujie Xie
SLShi Li
Shi Li
YZYong Zhang
Yong Zhang
Background: Recently, a novel vascular pattern characterized by vessels encapsulating tumor clusters (VETC) was reported to be related to poor clinical outcomes in patients with hepatocellular carcinoma (HCC). The objective of this study was to preliminarily assess the ability of metabolic parameters and radiomics features derived from 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to preoperatively predict VETC and prognosis in HCC patients. Methods: A total of 149 patients diagnosed with HCC from two institutions (The Third Affiliated Hospital of Sun Yat-sen University and Sun Yat-sen Memorial Hospital) were retrospectively enrolled and subsequently divided into a training cohort (n=103) and a test cohort (n=46) as external validation. The correlation between traditional image features on computed tomography (CT)/magnetic resonance imaging (MRI) and 18F-FDG PET/CT and VETC status were evaluated and compared. Radiomics features were extracted from 18F-FDG PET/CT images, followed by calculation of a radiomics score (Radscore). Univariate and multivariate logistic regression analyses were used to screen out the independent indicators. A nomogram model was developed based on Radscore and clinical indicators, and a clinical model was developed based on clinical indicators. The performance of the nomogram, clinical model, Radscore, as well as traditional PET parameter tumor-to-liver ratio (TLR) were evaluated using receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Disease-free survival (DFS) and overall survival (OS) rates were assessed using Kaplan-Meier survival analysis. Results: The difference in FDG parameter TLR between VETC-positive and VETC-negative HCC was found to be statistically significant (P<0.05), which was consistent with traditional CT/MRI imaging features. The Radscore was derived by calculating 13 selected radiomics features, comprising of six PET radiomics features and seven CT radiomics features. The nomogram model exhibited an area under the curve (AUC) of 0.908 [95% confidence interval (CI): 0.852–0.963; sensitivity: 0.855; specificity: 0.833] and 0.762 (95% CI: 0.624–0.900; sensitivity: 0.739; specificity: 0.739) in the training and test cohort, respectively. The disparity in the prediction of VETC status based on the nomogram model between DFS and OS was statistically comparable to that observed between VETC-positive and VETC-negative cases through pathological analysis (P<0.05). Conclusions: FDG metabolism is significantly associated with VETC status in HCC patients. A comprehensive nomogram model based on PET/CT radiomics and clinical indicators has potential for preoperative prediction of VETC as well as patient prognosis.

29 October 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
PLPak‐Lun Lam
Pak‐Lun Lam
YYYik‐Hoi Yeung
Yik‐Hoi Yeung
HKHei‐Yui Kai
Hei‐Yui Kai
YXYujie Xie
Yujie Xie
ZLZhengxiao Liu
Zhengxiao Liu
KWKa-Leung Wong
Ka-Leung Wong
Owing to safety concerns associated with previous gadolinium‐based magnetic resonance imaging (MRI) agents, pyclen‐based Gd chelates are emerging as promising alternatives. However, the development of pyclen‐based chelators has been hindered by synthetic challenges. In this work, we report two new pyclen‐based chelators featuring α ‐aryl‐substituents on two of the acetate arms. Using the Petasis reaction, two lanthanide chelators 3a and 3b were synthesized in just two steps from pyclen. 3a‐Gd exhibits superior coordination stability and relaxivity compared to previously reported Gd 3+ chelates of comparable molecular weight. It also has low cytotoxicity and produces a strong, long‐lasting in vivo MRI signal, enabling real‐time monitoring of tissues/organs, as demonstrated in heart, liver, and kidney imaging of mice. Additionally, the chelator also shows improved coordination kinetics for In 3+ , Tb 3+ , Lu 3+ , and Y 3+ , highlighting its potential for the development of a new class of next‐generation radiopharmaceuticals.

29 October 2026 in Angewandte Chemie
Verified
Journal Article
Open access
PLPak‐Lun Lam
Pak‐Lun Lam
YYYik‐Hoi Yeung
Yik‐Hoi Yeung
HKHei‐Yui Kai
Hei‐Yui Kai
YXYujie Xie
Yujie Xie
ZLZhengxiao Liu
Zhengxiao Liu
KWKa-Leung Wong
Ka-Leung Wong
Owing to safety concerns associated with previous gadolinium‐based magnetic resonance imaging (MRI) agents, pyclen‐based Gd chelates are emerging as promising alternatives. However, the development of pyclen‐based chelators has been hindered by synthetic challenges. In this work, we report two new pyclen‐based chelators featuring α ‐aryl‐substituents on two of the acetate arms. Using the Petasis reaction, two lanthanide chelators 3a and 3b were synthesized in just two steps from pyclen. 3a‐Gd exhibits superior coordination stability and relaxivity compared to previously reported Gd 3+ chelates of comparable molecular weight. It also has low cytotoxicity and produces a strong, long‐lasting in vivo MRI signal, enabling real‐time monitoring of tissues/organs, as demonstrated in heart, liver, and kidney imaging of mice. Additionally, the chelator also shows improved coordination kinetics for In 3+ , Tb 3+ , Lu 3+ , and Y 3+ , highlighting its potential for the development of a new class of next‐generation radiopharmaceuticals.

13 December 2025 in Asian Journal of Urology
Verified
Journal Article
Open access
YXYujie Xie
Yujie Xie
TYTing Yang
Ting Yang
SHSiqi Hu
Siqi Hu
ZSZijie Shen
Zijie Shen
GCGuangfeng Chen
Guangfeng Chen
YZYong Zhang
Yong Zhang